Abstract
PREVIEWIn recent years, new drug development and late-breaking research data have put treatment guidelines for diabetic nephropathy in a state of flux. In particular, trials of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), coupled with enhanced understanding of the renin-angiotensin pathway, have influenced recommendations for patient care. Here, Dr Bakris highlights both the steadfast features and the recent refinements of treatment guidelines for diabetic nephropathy. He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
